These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 1379160)
21. Raynaud's phenomenon and digital ischaemia--pharmacologic approach and alternative treatment options. Linnemann B; Erbe M Vasa; 2016; 45(3):201-12. PubMed ID: 27129065 [TBL] [Abstract][Full Text] [Related]
22. Infusion of a stable prostacyclin analogue, iloprost, to patients with peripheral vascular disease: lack of antiplatelet effect but risk of thromboembolism. Kovacs IB; Mayou SC; Kirby JD Am J Med; 1991 Jan; 90(1):41-6. PubMed ID: 1702580 [TBL] [Abstract][Full Text] [Related]
23. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Melian EB; Goa KL Drugs; 2002; 62(1):107-33. PubMed ID: 11790158 [TBL] [Abstract][Full Text] [Related]
24. Iloprost: new indication. Not adequately assessed. Prescrire Int; 1999 Apr; 8(40):49-50. PubMed ID: 10848061 [TBL] [Abstract][Full Text] [Related]
25. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708 [TBL] [Abstract][Full Text] [Related]
26. Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost. Lessiani G; Vazzana N; Cuccurullo C; Di Michele D; Laurora G; Sgrò G; Di Ruscio P; Simeone E; Di Iorio P; Lattanzio S; Liani R; Ferrante E; Davì G Thromb Haemost; 2011 Feb; 105(2):321-8. PubMed ID: 21103664 [TBL] [Abstract][Full Text] [Related]
27. Use of prostacyclin and its analogues in the treatment of cardiovascular disease. Fink AN; Frishman WH; Azizad M; Agarwal Y Heart Dis; 1999; 1(1):29-40. PubMed ID: 11720602 [TBL] [Abstract][Full Text] [Related]
28. Outpatient treatment of severe peripheral ischemia with intravenous intermittent low-dose iloprost. An open pilot study. Banyai S; Jenelten R; Wagner S; Allmann J; Banyai M; Koppensteiner R Int Angiol; 2002 Mar; 21(1):36-43. PubMed ID: 11941272 [TBL] [Abstract][Full Text] [Related]
29. [Iloprost for severe Raynaud's phenomenon and ischaemic ulcers related with systemic diseases]. García Hernández FJ; Ocaña Medina C; Mateos Romero L; Molinillo López J; Arias Zambrano A; González León R; Sánchez Román J Med Clin (Barc); 2004 Apr; 122(13):501-4. PubMed ID: 15104947 [TBL] [Abstract][Full Text] [Related]
30. [The pharmacology and clinical aspects of the prostanoids]. Ambrosioni E; Degli Esposti D Ann Ital Med Int; 1993 Oct; 8 Suppl():59S-65S. PubMed ID: 8117524 [TBL] [Abstract][Full Text] [Related]
31. A randomized trial of iloprost in patients with intermittent claudication. Creager MA; Pande RL; Hiatt WR Vasc Med; 2008 Feb; 13(1):5-13. PubMed ID: 18372433 [TBL] [Abstract][Full Text] [Related]
32. Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders. Murdoch D; Brogden RN Drugs; 1991 May; 41(5):737-79. PubMed ID: 1712708 [TBL] [Abstract][Full Text] [Related]
33. Higher body mass index is associated with a lower iloprost infusion rate tolerance and higher iloprost-related adverse events in patients with systemic sclerosis. Bixio R; Adami G; Bertoldo E; Giollo A; Morciano A; Bertelle D; Orsolini G; Idolazzi L; Rossini M; Viapiana O Ther Adv Musculoskelet Dis; 2022; 14():1759720X221137125. PubMed ID: 36439640 [TBL] [Abstract][Full Text] [Related]
34. Cardiac surgery in patients with heparin-induced thrombocytopenia using preoperatively determined dosages of iloprost. Antoniou T; Kapetanakis EI; Theodoraki K; Rellia P; Thanopoulos A; Kotiou M; Zarkalis D; Alivizatos P Heart Surg Forum; 2002; 5(4):354-7. PubMed ID: 12538117 [TBL] [Abstract][Full Text] [Related]
36. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol. Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290 [TBL] [Abstract][Full Text] [Related]
37. Comparison of inhibitory actions of prostacyclin and a new prostacyclin analogue on the aggregation of human platelet in whole blood. Saniabadi AR; Belch JJ; Lowe GD; Barbenel JC; Forbes CD Haemostasis; 1987; 17(3):147-53. PubMed ID: 2440771 [TBL] [Abstract][Full Text] [Related]
38. [Iloprost for the treatment of systemic sclerosis]. Hachulla E; Launay D; Hatron PY Presse Med; 2008 May; 37(5 Pt 2):831-9. PubMed ID: 18035518 [TBL] [Abstract][Full Text] [Related]
39. Carotid endarterectomy in patients with heparin-induced platelet activation: comparative efficacy of aspirin and iloprost (ZK36374). Kappa JR; Cottrell ED; Berkowitz HD; Fisher CA; Sobel M; Ellison N; Addonizio VP J Vasc Surg; 1987 May; 5(5):693-701. PubMed ID: 2437338 [TBL] [Abstract][Full Text] [Related]
40. Is it possible to improve outcome in patients undergoing surgery for acute limb ischemia? Can iloprost, a prostacyclin analogue, be helpful? de Donato G; Gussoni G; de Donato G Chir Ital; 2004; 56(6):769-80. PubMed ID: 15771029 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]